|
covid-19 |
126 |
|
sars-cov-2 |
98 |
|
coronavirus |
34 |
|
sars-cov |
29 |
|
interprofessional education |
28 |
|
partnership model |
28 |
|
social interaction anxiety |
28 |
|
adult |
27 |
|
influenza |
27 |
|
aged |
25 |
|
humans |
25 |
|
viral load |
25 |
|
children |
23 |
|
male |
22 |
|
omicron |
20 |
|
saliva |
20 |
|
ace2 |
19 |
|
female |
19 |
|
interferon |
19 |
|
middle aged |
19 |
|
susceptibility |
19 |
|
influenza virus |
18 |
|
neutralizing antibody |
18 |
|
age |
17 |
|
antibody |
17 |
|
pathogenesis |
17 |
|
h7n9 |
16 |
|
hong kong - epidemiology |
16 |
|
interferon beta-1b |
16 |
|
pandemic |
16 |
|
serology |
16 |
|
transmission |
16 |
|
vaccine |
16 |
|
aged, 80 and over |
15 |
|
child |
15 |
|
diagnosis |
15 |
|
h5n1 |
15 |
|
hemagglutinin |
15 |
|
influenza, human - epidemiology - virology |
15 |
|
live attenuated vaccine |
15 |
|
mouse |
15 |
|
prognosis |
15 |
|
animal experiment |
14 |
|
biomarkers |
14 |
|
dialysis |
14 |
|
immune activation |
14 |
|
intestine |
14 |
|
mers-cov |
14 |
|
mucosal immunity |
14 |
|
replication |
14 |
|
sars |
14 |
|
thyroid function tests |
14 |
|
adolescent |
13 |
|
cell line |
13 |
|
cytokine and chemokine response |
13 |
|
immune response |
13 |
|
influenza, human - virology |
13 |
|
nsp1 |
13 |
|
rhizopus microsporus |
13 |
|
rnai |
13 |
|
sace2 |
13 |
|
sars-cov-2 variants |
13 |
|
species index: fungi |
13 |
|
thyroid gland |
13 |
|
viral replication |
13 |
|
adolescents |
12 |
|
animal |
12 |
|
animals |
12 |
|
chinese |
12 |
|
convalescence |
12 |
|
coronavirus disease 2019 |
12 |
|
disease outbreaks |
12 |
|
false positive |
12 |
|
infectivity |
12 |
|
influenza a virus |
12 |
|
influenza a virus, h1n1 subtype - genetics |
12 |
|
kawasaki disease |
12 |
|
metabolomics |
12 |
|
mortality |
12 |
|
omicron variant |
12 |
|
plasma |
12 |
|
sars-cov-2 rbd igg |
12 |
|
t cell response |
12 |
|
2′-o-methyltransferase |
11 |
|
animal cell |
11 |
|
animal tissue |
11 |
|
anthranilic acid |
11 |
|
antibody titer |
11 |
|
bat |
11 |
|
broad spectrum |
11 |
|
chemicals and cas registry numbers |
11 |
|
chemokine |
11 |
|
china |
11 |
|
coinfection |
11 |
|
cytokine |
11 |
|
elderly |
11 |
|
endoplasmic reticulum |
11 |
|
feces analysis |
11 |
|
hong kong |
11 |
|
human immunodeficiency virus |
11 |
|
incidence |
11 |
|
murine |
11 |
|
n501y |
11 |
|
nsp16 |
11 |
|
pneumonia |
11 |
|
rat |
11 |
|
sterilizing immunity |
11 |
|
stool |
11 |
|
t-cell response |
11 |
|
thyroiditis |
11 |
|
adaptation |
10 |
|
anosmia |
10 |
|
antigen-presentation |
10 |
|
birds - virology |
10 |
|
burkholderia pseudomallei |
10 |
|
cell line, tumor |
10 |
|
cell tropism |
10 |
|
chick embryo |
10 |
|
child, preschool |
10 |
|
coronavirus - immunology - pathogenicity - physiology |
10 |
|
coronavirus infections - immunology - virology |
10 |
|
covid19 |
10 |
|
cytokines - biosynthesis - immunology |
10 |
|
cytokines - blood |
10 |
|
d222g |
10 |
|
d225g |
10 |
|
damplicon |
10 |
|
dogs |
10 |
|
h1n1 |
10 |
|
hemagglutinin glycoproteins, influenza virus - genetics - metabolism |
10 |
|
human neutralizing antibody |
10 |
|
infant |
10 |
|
influenza a virus, h1n1 subtype - genetics - pathogenicity |
10 |
|
influenza a virus, h1n1 subtype - isolation and purification |
10 |
|
influenza a virus, h1n1 subtype - physiology |
10 |
|
influenza a virus, h5n1 subtype - physiology |
10 |
|
influenza h1n1 |
10 |
|
influenza in birds - virology |
10 |
|
influenza vaccine |
10 |
|
influenza, human - immunology - pathology - virology |
10 |
|
intradermal |
10 |
|
linker-immunodominant site |
10 |
|
lung injury |
10 |
|
medical sciences |
10 |
|
melioidosis |
10 |
|
mutation - genetics |
10 |
|
mycobacterium tuberculosis |
10 |
|
nasal turbinate |
10 |
|
novel |
10 |
|
olfactory dysfunction |
10 |
|
phage display |
10 |
|
pneumonia, viral - immunology - virology |
10 |
|
receptor binding domain |
10 |
|
screening |
10 |
|
seroprevalence |
10 |
|
sialic acid |
10 |
|
smell impairment |
10 |
|
spike protein |
10 |
|
swine - virology |
10 |
|
swine diseases - virology |
10 |
|
swine-origin |
10 |
|
temperature |
10 |
|
upper respiratory tract |
10 |
|
virus replication |
10 |
|
virus replication - physiology |
10 |
|
young adult |
10 |
|
age-stratified |
9 |
|
aged mice |
9 |
|
airborne infection |
9 |
|
airway organoid |
9 |
|
animal model |
9 |
|
antibodies, neutralizing - blood |
9 |
|
antibodies, viral - biosynthesis |
9 |
|
antibodies, viral - blood |
9 |
|
apoptosis |
9 |
|
asia |
9 |
|
ba.5.2 |
9 |
|
bacteremia |
9 |
|
bagg albino mouse |
9 |
|
bioaerosols |
9 |
|
cell surface |
9 |
|
chest x-ray |
9 |
|
clinical outcome |
9 |
|
cohort studies |
9 |
|
controlled study |
9 |
|
coronavac |
9 |
|
emerging |
9 |
|
entry |
9 |
|
epidemiology |
9 |
|
euthyroid sick syndromes |
9 |
|
ex vivo |
9 |
|
fc-rbd |
9 |
|
genotype |
9 |
|
human primary nasal epithelial cells |
9 |
|
illumina sequencing |
9 |
|
immune imprinting |
9 |
|
immune protection |
9 |
|
inactivated vaccine |
9 |
|
influenza a virus, h1n1 subtype - genetics - isolation and purification - physiology |
9 |
|
influenza a virus, h1n1 subtype - immunology - pathogenicity |
9 |
|
internalization |
9 |
|
microbial sensitivity tests |
9 |
|
mutation |
9 |
|
neutralizing antibodies |
9 |
|
nomogram |
9 |
|
nucleolin |
9 |
|
operating rooms |
9 |
|
orthomyxoviridae infections - immunology - mortality - physiopathology - virology |
9 |
|
outbreak |
9 |
|
point-of-care testing |
9 |
|
post-ba.2/5 subvariants |
9 |
|
prediction model |
9 |
|
proximal differentiation |
9 |
|
retrospective studies |
9 |
|
rhinovirus |
9 |
|
risk factors |
9 |
|
sars-cov-2 variants of concern |
9 |
|
severity of illness index |
9 |
|
specific |
9 |
|
t-lymphocytes - immunology |
9 |
|
travel history |
9 |
|
vaccination |
9 |
|
vopba |
9 |
|
weanling mice |
9 |
|
white cell count |
9 |
|
xbb.1 |
9 |
|
2009 h1n1 influenza |
8 |
|
25-hydroxycholesterol |
8 |
|
3clpro inhibitor |
8 |
|
a(h1n1)pdm09 |
8 |
|
a(h3n2) |
8 |
|
acute infection |
8 |
|
age factors |
8 |
|
allosteric-site inhibitor |
8 |
|
am580 |
8 |
|
animal models |
8 |
|
anti-bacterial agents - pharmacology |
8 |
|
anti-bacterial agents - therapeutic use |
8 |
|
antibody blood level |
8 |
|
antibody detection |
8 |
|
antibody formation |
8 |
|
antibody response |
8 |
|
antiviral |
8 |
|
asymptomatic |
8 |
|
asymptomatic infection |
8 |
|
autoimmunity |
8 |
|
autopsy |
8 |
|
avian influenza virus |
8 |
|
b-cell suppression |
8 |
|
betacoronavirus |
8 |
|
biomarker |
8 |
|
bnt162b2 mrna covid-19 vaccines |
8 |
|
broad-spectrum antiviral treatment |
8 |
|
case study |
8 |
|
caspase |
8 |
|
chemical genetics |
8 |
|
chicken |
8 |
|
china - epidemiology |
8 |
|
chronic hepatitis b |
8 |
|
clarithromycin |
8 |
|
conjunctiva |
8 |
|
convalescent |
8 |
|
covid-19 vaccine |
8 |
|
covid‐19 |
8 |
|
cross-reactive |
8 |
|
delns1-ncov-rbd laiv |
8 |
|
dendritic cell |
8 |
|
diagnostic |
8 |
|
disease outbreaks - statistics & numerical data |
8 |
|
early |
8 |
|
emc |
8 |
|
feces - virology |
8 |
|
ganglioside gm1 antibody |
8 |
|
glycolipids |
8 |
|
hamster |
8 |
|
hcov-emc |
8 |
|
hemagglutination inhibition tests |
8 |
|
hepatitis b vaccination |
8 |
|
high throughput screening |
8 |
|
high-risk |
8 |
|
hku1 |
8 |
|
hla‐dp |
8 |
|
hospitalized |
8 |
|
human |
8 |
|
hypercytokinemia |
8 |
|
ifn‐γ pathway |
8 |
|
il-8 |
8 |
|
imiquimod |
8 |
|
infection |
8 |
|
inflammation |
8 |
|
influenza a virus, h1n1 subtype - genetics - immunology - isolation and purification |
8 |
|
influenza a virus, h1n1 subtype - genetics - isolation & purification - physiology |
8 |
|
influenza a virus, h1n1 subtype - immunology |
8 |
|
influenza a virus, h1n1 subtype - isolation & purification - pathogenicity |
8 |
|
influenza vaccines - immunology |
8 |
|
influenza, human - epidemiology - pathology - virology |
8 |
|
influenza, human - immunology |
8 |
|
innate immunity |
8 |
|
interferon lambda 1 |
8 |
|
intranasal |
8 |
|
kir genetics |
8 |
|
lipid |
8 |
|
marmosets |
8 |
|
mask |
8 |
|
metabolomic |
8 |
|
mitochondrial dysfunction |
8 |
|
nanopore sequencing |
8 |
|
naproxen |
8 |
|
neutralization |
8 |
|
nk cells |
8 |
|
obesity |
8 |
|
oc43 |
8 |
|
organic acid |
8 |
|
oseltamivir |
8 |
|
phase-1 |
8 |
|
phospholipids |
8 |
|
phylogenetic tree |
8 |
|
remdesivir |
8 |
|
respiratory system - virology |
8 |
|
respiratory tract infection |
8 |
|
reverse genetics |
8 |
|
reverse transcriptase polymerase chain reaction |
8 |
|
rna, viral - genetics |
8 |
|
rt-pcr |
8 |
|
rt‐pcr |
8 |
|
sars‐cov‐2 |
8 |
|
seasons |
8 |
|
serial |
8 |
|
shedding |
8 |
|
sphingolipids |
8 |
|
spike mutant |
8 |
|
spike s1/s2 mutant |
8 |
|
spleen |
8 |
|
t lymphocytes |
8 |
|
tlr7 agonist |
8 |
|
tonsil |
8 |
|
translation to patients |
8 |
|
urine |
8 |
|
urine - virology |
8 |
|
vaccine-related myocarditis |
8 |
|
viral load - physiology |
8 |
|
virus cultivation |
8 |
|
virus shedding |
8 |
|
a(h1n1)pdm09 influenza |
7 |
|
a(h7n9) influenza |
7 |
|
adiponectin |
7 |
|
adjuvant |
7 |
|
amino acid substitution |
7 |
|
antiviral agents - administration and dosage - therapeutic use |
7 |
|
autoantibodies |
7 |
|
avian influenza |
7 |
|
avian influenza a/h7n9 virus |
7 |
|
bacteriological techniques - methods |
7 |
|
caco-2 |
7 |
|
cardiac infection |
7 |
|
cardiomyocytes |
7 |
|
cell culture |
7 |
|
community |
7 |
|
culture media - chemistry |
7 |
|
cva16 |
7 |
|
defective interfering viral genome |
7 |
|
diarrhea - epidemiology - microbiology |
7 |
|
disease severity |
7 |
|
escherichia coli |
7 |
|
ev-a71 |
7 |
|
evaluation |
7 |
|
furin cleavage prra motif |
7 |
|
genetic variation |
7 |
|
heart |
7 |
|
hemagglutinins - genetics |
7 |
|
high infection rate |
7 |
|
icu patient |
7 |
|
immunity |
7 |
|
immunoglobulin g - blood |
7 |
|
immunological profiles |
7 |
|
immunology |
7 |
|
influenza, human - drug therapy - epidemiology - virology |
7 |
|
interferon antagonist |
7 |
|
intestinal organoids |
7 |
|
klebsiella infections - epidemiology - microbiology |
7 |
|
klebsiella oxytoca - classification - genetics - isolation and purification - pathogenicity |
7 |
|
leptin |
7 |
|
lightmix e-gene |
7 |
|
lung eqtl |
7 |
|
mice |
7 |
|
miltefosine |
7 |
|
monoinfection |
7 |
|
orf6 |
7 |
|
oseltamivir - administration and dosage - therapeutic use |
7 |
|
pathogenicity |
7 |
|
phylodynamic |
7 |
|
phylogenetic |
7 |
|
plpro |
7 |
|
post–acute covid-19 syndrome |
7 |
|
real-time rt-pcr |
7 |
|
reinfection |
7 |
|
respiratory viruses |
7 |
|
route of transmission |
7 |
|
severe |
7 |
|
severe acute respiratory syndrome |
7 |
|
single molecule real time sequencing |
7 |
|
single-tube nested |
7 |
|
stability |
7 |
|
tfh |
7 |
|
time factors |
7 |
|
tmprss2 |
7 |
|
viral genome |
7 |
|
viral isolation |
7 |
|
viral variants |
7 |
|
virology |
7 |
|
whole-genome sequencing |
7 |
|
2019 novel coronavirus |
6 |
|
acquired immunodeficiency syndrome - complications - etiology |
6 |
|
antibody assay |
6 |
|
antigenic cartography |
6 |
|
antigenic distance |
6 |
|
antigenic field |
6 |
|
aspergillus |
6 |
|
astrovirus |
6 |
|
autoantibodies - blood |
6 |
|
autoantibody |
6 |
|
automated |
6 |
|
biomedicine |
6 |
|
booster vaccine |
6 |
|
bowel preparation |
6 |
|
broad-spectrum |
6 |
|
burkholderia infections - etiology - immunology |
6 |
|
chronic kidney disease |
6 |
|
clarithromycin - adverse effects - contraindications |
6 |
|
clr |
6 |
|
colchicine - adverse effects - contraindications |
6 |
|
cost |
6 |
|
coxsackievirus a6 |
6 |
|
daptomycin |
6 |
|
decolonization |
6 |
|
diagnostic assay |
6 |
|
diagnostic test evaluation |
6 |
|
diagnostics |
6 |
|
drug interactions |
6 |
|
enzymatic immunoassay |
6 |
|
eosinophil |
6 |
|
face mask |
6 |
|
flow cytometry |
6 |
|
genome |
6 |
|
genome subtraction |
6 |
|
gram-positive bacterial infections - epidemiology - microbiology - mortality - physiopathology |
6 |
|
guanosine |
6 |
|
hand-foot-and-mouth disease |
6 |
|
health care workers |
6 |
|
hemagglutinins, viral - metabolism |
6 |
|
host-targeted antiviral |
6 |
|
human rhinovirus |
6 |
|
immunogenicity |
6 |
|
influenza a virus, h1n1 subtype - metabolism |
6 |
|
intensive care unit |
6 |
|
interferon-gamma - immunology |
6 |
|
internal medicine |
6 |
|
intra-host diversity |
6 |
|
kidney failure - complications |
6 |
|
lactobacillus rhamnosus gg |
6 |
|
leukemia |
6 |
|
linezolid |
6 |
|
medical microbiology |
6 |
|
memory t cell |
6 |
|
metabolites |
6 |
|
middle east |
6 |
|
mincle |
6 |
|
mitochondrial dysfunction (md) |
6 |
|
multivariate analysis |
6 |
|
mycophenolic acid |
6 |
|
mycoses - etiology - immunology |
6 |
|
nasopharyngeal |
6 |
|
nasopharyngeal swab |
6 |
|
next-generation sequencing |
6 |
|
nsp2 |
6 |
|
osteomyelitis |
6 |
|
pcr |
6 |
|
peritonitis |
6 |
|
pneumocytis |
6 |
|
polyethylene glycol |
6 |
|
polymerase inhibitor |
6 |
|
polymorphism, genetic |
6 |
|
pooling |
6 |
|
proinflammatory response |
6 |
|
recombination |
6 |
|
respiratory |
6 |
|
respiratory failure |
6 |
|
respiratory syncytial virus |
6 |
|
respiratory virus |
6 |
|
ribavirin |
6 |
|
rlr |
6 |
|
rodents |
6 |
|
sars virus |
6 |
|
sars-cov-1 |
6 |
|
seasonality |
6 |
|
secondary bacterial pneumonia |
6 |
|
seizure |
6 |
|
shewanella - classification - drug effects - isolation & purification - pathogenicity |
6 |
|
t-cell functionality |
6 |
|
tetrapeptide |
6 |
|
tract |
6 |
|
vaccine seed strain selection |
6 |
|
vancomycin-resistant enterococci |
6 |
|
viremia - diagnosis - epidemiology |
6 |
|
virus discovery |
6 |
|
whole genome |
6 |
|
wuhan |
6 |
|
abbott real time hcv genotype ii |
5 |
|
acetic acid |
5 |
|
actinomycetales - genetics - isolation & purification |
5 |
|
actinomycetales infections - microbiology |
5 |
|
adenosine deaminase |
5 |
|
adrenal cortex hormones - administration and dosage - adverse effects |
5 |
|
agar block smear |
5 |
|
amniotomy |
5 |
|
anaerobic bacterium |
5 |
|
antibiotic resistance |
5 |
|
antibiotic sensitivity |
5 |
|
antibody affinity |
5 |
|
antigens, viral - analysis |
5 |
|
antimicrobial drug resistance |
5 |
|
arthralgia |
5 |
|
arthritis |
5 |
|
arthritis, infectious - microbiology |
5 |
|
avian influenza virus h5n1 clade 2.3.4.4b |
5 |
|
b.1.1.7b.1.351 |
5 |
|
bacterial endocarditis |
5 |
|
bacterial typing techniques |
5 |
|
bacteriuria |
5 |
|
base sequence |
5 |
|
biofilms |
5 |
|
booster |
5 |
|
calcineurin |
5 |
|
caliciviridae infections - epidemiology - prevention and control - transmission |
5 |
|
candida |
5 |
|
catalase |
5 |
|
cattle |
5 |
|
ccl22 |
5 |
|
clostridium difficile |
5 |
|
clostridium difficile - classification - genetics - isolation and purification |
5 |
|
covid-19 severity |
5 |
|
cross infection - epidemiology - prevention and control - transmission |
5 |
|
cross infection - microbiology - prevention and control - transmission |
5 |
|
cross infection - prevention and control - transmission - virology |
5 |
|
ctx-m-14 beta-lactamase |
5 |
|
ddx5 |
5 |
|
disease outbreaks - prevention and control - statistics and numerical data |
5 |
|
drug dosage form comparison |
5 |
|
drug dose comparison |
5 |
|
emerging infectious disease |
5 |
|
enterobacteriaceae |
5 |
|
enterocolitis, pseudomembranous - epidemiology - microbiology |
5 |
|
fecal-to-oral transmission |
5 |
|
fracture fixation |
5 |
|
genotyping |
5 |
|
h1n1 virus |
5 |
|
h9n2 |
5 |
|
handwashing - methods |
5 |
|
hepatitis c |
5 |
|
hospital |
5 |
|
hybrid immunity |
5 |
|
immunocompromised host |
5 |
|
immunotherapy - methods |
5 |
|
implant |
5 |
|
infection control |
5 |
|
infection control - methods |
5 |
|
infection control bundle |
5 |
|
influenza a virus, h1n1 subtype - immunology - isolation and purification - pathogenicity |
5 |
|
influenza a virus, h3n2 subtype - genetics - isolation and purification |
5 |
|
influenza a virus, h7n9 subtype - genetics - isolation and purification |
5 |
|
influenza, human - diagnosis - virology |
5 |
|
influenza, human - mortality - therapy - virology |
5 |
|
influenza, human - prevention and control - transmission - virology |
5 |
|
invasive infections |
5 |
|
its sequencing |
5 |
|
keywords sars-cov-2 |
5 |
|
kytococcus schroeteri |
5 |
|
luminex nxtag |
5 |
|
malaria - diagnosis - parasitology |
5 |
|
medical sciences biology |
5 |
|
methicillin-resistant staphylococcus aureus - isolation and purification |
5 |
|
microbiology |
5 |
|
molecular sequence data |
5 |
|
mucorales |
5 |
|
myeloperoxidase |
5 |
|
nasopharyngeal specimen |
5 |
|
neutralizing antibody spike protein receptor binding domain |
5 |
|
nfat |
5 |
|
nmr-based urinalysis |
5 |
|
norovirus - genetics - isolation and purification |
5 |
|
nosocomial infection |
5 |
|
nucleic acid amplification |
5 |
|
osteomyelitis - microbiology |
5 |
|
paediatrics |
5 |
|
patient isolation - methods |
5 |
|
phaeoacremonium parasiticum |
5 |
|
plasma - immunology |
5 |
|
plasmids |
5 |
|
plasmodium malariae - genetics - isolation and purification |
5 |
|
point-of-care systems |
5 |
|
policy |
5 |
|
polymerase chain reaction |
5 |
|
population susceptibility |
5 |
|
prisma |
5 |
|
prosthesis-related infections |
5 |
|
prosthesis-related infections - microbiology |
5 |
|
rcan3 |
5 |
|
recombinant |
5 |
|
renal abscess |
5 |
|
respiratory tract infections |
5 |
|
restriction fragment length polymorphism |
5 |
|
ribotype 027 |
5 |
|
ribotyping |
5 |
|
rna virus |
5 |
|
sars-cov-2 n501y variant |
5 |
|
serosurveillance |
5 |
|
staphylococcal infections - microbiology - prevention and control - transmission |
5 |
|
surgical wound infection |
5 |
|
t cell |
5 |
|
trimethylamine |
5 |
|
urinary tract infection |
5 |
|
viral persistence |
5 |
|
virus evolution |
5 |
|
voc |
5 |
|
β-tubulin gene sequencing |
5 |
|
adenovirus |
4 |
|
agar gel electrophoresis |
4 |
|
ancylostoma duodenale |
4 |
|
anisakis simplex |
4 |
|
antibiotic prophylaxis |
4 |
|
antibiotics |
4 |
|
antibodies |
4 |
|
antigens, cd55 - genetics - immunology |
4 |
|
aortic aneurysm, abdominal - complications - diagnosis - pathology - therapy |
4 |
|
ascaris lumbricoides |
4 |
|
avian |
4 |
|
azithromycin - therapeutic use |
4 |
|
b cell |
4 |
|
ba.2.86 |
4 |
|
brain diseases - microbiology |
4 |
|
broadly neutralizing antibody |
4 |
|
capnocytophaga - isolation and purification |
4 |
|
cardiac complications |
4 |
|
carrier state - microbiology |
4 |
|
cecal diseases - diagnosis - parasitology |
4 |
|
cell death |
4 |
|
cephalosporin |
4 |
|
cerebrospinal fluid |
4 |
|
chronic infection |
4 |
|
clinical |
4 |
|
cluster analysis |
4 |
|
co-metabolites |
4 |
|
colony count, microbial |
4 |
|
coronavirus infection |
4 |
|
coxiella burnetii |
4 |
|
cross infection - microbiology |
4 |
|
cytokines |
4 |
|
dermatomycoses - microbiology |
4 |
|
detection |
4 |
|
dna fingerprinting |
4 |
|
dna, bacterial - genetics |
4 |
|
drug resistance, multiple, bacterial |
4 |
|
eg.5 |
4 |
|
electrophoresis, gel, pulsed-field |
4 |
|
endocarditis, bacterial - complications - diagnosis - therapy |
4 |
|
endocarditis, bacterial - microbiology |
4 |
|
environmental microbiology |
4 |
|
epitope |
4 |
|
evolution |
4 |
|
extended-spectrum beta-lactamase (esbl) |
4 |
|
fatal outcome |
4 |
|
fluoroquinolones |
4 |
|
follow-up studies |
4 |
|
fungi - isolation and purification |
4 |
|
gastrointestinal diseases - microbiology |
4 |
|
genes, fungal |
4 |
|
genetic predisposition to disease |
4 |
|
genomic rearrangement |
4 |
|
gram-negative bacterial infections - diagnosis - microbiology |
4 |
|
gram-positive bacterial infections |
4 |
|
h10n8 |
4 |
|
histopathology |
4 |
|
hospitalisation |
4 |
|
host susceptibilities |
4 |
|
iga |
4 |
|
immune breakthrough |
4 |
|
immune impairment |
4 |
|
inactivated influenza |
4 |
|
inbred mouse lines |
4 |
|
influenza (h7n9) virus |
4 |
|
influenza a virus - classification - isolation and purification |
4 |
|
influenza a virus, h7n9 subtype - immunology - isolation and purification |
4 |
|
influenza a virus, h7n9 subtype - isolation and purification |
4 |
|
influenza in birds - epidemiology - virology |
4 |
|
influenza vaccines |
4 |
|
influenza, human - blood - pathology - virology |
4 |
|
influenza, human - epidemiology - immunology - virology |
4 |
|
influenza, human - epidemiology - prevention and control - transmission - virology |
4 |
|
influenza, human - genetics - immunology - pathology - virology |
4 |
|
intussusception - diagnosis - parasitology |
4 |
|
isolation |
4 |
|
jn.1 |
4 |
|
kidney failure, chronic - therapy |
4 |
|
kidney transplantation |
4 |
|
l336m |
4 |
|
lactococcus |
4 |
|
liver transplantation |
4 |
|
macrolides - therapeutic use |
4 |
|
maxillary sinusitis - complications - microbiology |
4 |
|
methicillin resistance |
4 |
|
meticillin-resistant staphylococcus aureus |
4 |
|
middle east respiratory syndrome coronavirus (mers-cov) |
4 |
|
mirna-seq |
4 |
|
molecular sequence numbers |
4 |
|
monocytes |
4 |
|
mrna-seq |
4 |
|
mucorales - isolation & purification - physiology |
4 |
|
mucormycosis - microbiology |
4 |
|
multiple myeloma - complications - diagnosis - pathology - therapy |
4 |
|
mycoplasma pneumoniae - metabolism |
4 |
|
nasal colonisation |
4 |
|
nasopharyngeal neoplasms - complications - therapy |
4 |
|
nasopharynx - virology |
4 |
|
nmr spectroscopy |
4 |
|
nose - microbiology |
4 |
|
nose diseases - microbiology |
4 |
|
novel coronaviruses |
4 |
|
ns1 |
4 |
|
occupational exposure |
4 |
|
omicron breakthrough infection |
4 |
|
ophthalmology and optometry |
4 |
|
orf8 |
4 |
|
pa |
4 |
|
paracetamol |
4 |
|
parainfluenza virus |
4 |
|
peptide |
4 |
|
peritoneal dialysis - adverse effects |
4 |
|
peritonitis - drug therapy - epidemiology - microbiology |
4 |
|
pge2 |
4 |
|
phylogeny |
4 |
|
pneumococcal infections - complications - diagnosis - pathology - therapy |
4 |
|
pneumonia - drug therapy - radiography |
4 |
|
polymorphism, single nucleotide |
4 |
|
poultry |
4 |
|
poultry workers |
4 |
|
pregnancy |
4 |
|
prenatal care |
4 |
|
prevention of xbb.1.5 transmission |
4 |
|
prospective studies |
4 |
|
proteinase k |
4 |
|
psoas abscess - microbiology |
4 |
|
q fever |
4 |
|
q fever - diagnosis - epidemiology |
4 |
|
quantitative metabolomics |
4 |
|
re-infection |
4 |
|
resistance |
4 |
|
serological surveillance |
4 |
|
severe acute respiratory syndrome coronavirus (sars-cov) |
4 |
|
staphylococcal infections - microbiology |
4 |
|
staphylococcus aureus - classification - drug effects - isolation & purification |
4 |
|
streptococcal infections - epidemiology - microbiology |
4 |
|
streptococcus bovis |
4 |
|
streptococcus bovis - isolation & purification |
4 |
|
structural fitness of antibody |
4 |
|
survival rate - trends |
4 |
|
temporal dynamics |
4 |
|
tickborne diseases |
4 |
|
trichuriasis - complications |
4 |
|
trichuris - isolation and purification |
4 |
|
zoonoses |
4 |
|
β-lactams |
4 |
|
amino acid deletion |
3 |
|
asthma |
3 |
|
attitude of health personnel |
3 |
|
atypical pneumonia |
3 |
|
avian influenza h7n9 |
3 |
|
bacterial infections - diagnosis - drug therapy |
3 |
|
beauty |
3 |
|
beta-lactam resistance |
3 |
|
breast milk |
3 |
|
capd |
3 |
|
ceftazidime - blood - pharmacology - urine |
3 |
|
ceftriaxone - blood - pharmacology - urine |
3 |
|
combination antiretroviral therapy |
3 |
|
community-acquired infections - drug therapy - microbiology |
3 |
|
community-acquired legionellosis |
3 |
|
cytokine-induced killer cell therapy |
3 |
|
d614g |
3 |
|
diagnostic test |
3 |
|
drug utilization - standards |
3 |
|
ebola virus disease |
3 |
|
ebolavirus |
3 |
|
empyema |
3 |
|
epidemic |
3 |
|
escherichia coli - drug effects - enzymology - isolation and purification |
3 |
|
guideline adherence - statistics & numerical data |
3 |
|
h1n1 subtype |
3 |
|
health services research |
3 |
|
hiv-1 |
3 |
|
hospitals |
3 |
|
human betacoronavirus 2c emc/2012 |
3 |
|
humanized mouse |
3 |
|
immune |
3 |
|
immunocompetence |
3 |
|
infectious mononucleosis - physiopathology - virology |
3 |
|
influenza b |
3 |
|
integrin 4β7 |
3 |
|
laribacter hongkongensis |
3 |
|
macrolides |
3 |
|
management |
3 |
|
metapneumovirus - pathogenicity |
3 |
|
methicillin-resistant staphylococcus aureus - isolation & purification |
3 |
|
middle east respiratory syndrome |
3 |
|
mycobacterium abscessus |
3 |
|
nosocomial legionellosis |
3 |
|
orf3a |
3 |
|
orf3b |
3 |
|
organizational policy |
3 |
|
paramyxoviridae infections - physiopathology - virology |
3 |
|
pathology |
3 |
|
prescriptions - standards |
3 |
|
q57h |
3 |
|
rm-act-1 |
3 |
|
sepsis |
3 |
|
staphylococcal infections - drug therapy - microbiology |
3 |
|
treatment |
3 |
|
vedolizumab |
3 |
|
victoria lineage |
3 |
|
virulence factors |
3 |
|
west africa |
3 |
|
antibodies, viral - immunology |
2 |
|
antigens, fungal - cerebrospinal fluid |
2 |
|
cerebrospinal fluid shunts - methods |
2 |
|
cryptococcus neoformans - classification - genetics - immunology - isolation & purification |
2 |
|
false negative reactions |
2 |
|
influenza vaccines - administration and dosage |
2 |
|
injections, intradermal |
2 |
|
meningitis, cryptococcal - cerebrospinal fluid - diagnosis |
2 |
|
non-tuberculous mycobacteria |
2 |
|
phenotype |
2 |
|
prostheses and implants - microbiology |
2 |
|
infective endocarditis |
1 |
|
new chemoprophylaxis guidelines |
1 |
|
therapeutics |
1 |
